World's First Lassa Vaccine Close To Human Testing
Themis Bioscience a leading company developing prophylactic vaccines against emerging tropical infectious diseases, has indicated plans to start in-human testing of its vaccine against the deadly Lassa fever disease as early as this year, with help from $37.5 million in funding from the public-private vaccine alliance, the Coalition for Epidemic Preparedness Innovations.
As an unprecedented Lassa fever outbreak devastates Nigeria, Themis aims to generate safety and immunogenicity data in about three years, to lay the groundwork for emergency use.
The first step is to enter the clinic early next year, or even late this year, Themis CEO Erich Tauber told FiercePharma.